Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Risk of relapse after discontinuation of tocilizumab therapy in giant cell arteritis.

Adler S, Reichenbach S, Gloor A, Yerly D, Cullmann JL, Villiger PM.

Rheumatology (Oxford). 2019 Sep 1;58(9):1639-1643. doi: 10.1093/rheumatology/kez091.

PMID:
30915462
2.

Human "TH9" cells are a subpopulation of PPAR-γ+ TH2 cells.

Micossé C, von Meyenn L, Steck O, Kipfer E, Adam C, Simillion C, Seyed Jafari SM, Olah P, Yawlkar N, Simon D, Borradori L, Kuchen S, Yerly D, Homey B, Conrad C, Snijder B, Schmidt M, Schlapbach C.

Sci Immunol. 2019 Jan 18;4(31). pii: eaat5943. doi: 10.1126/sciimmunol.aat5943.

PMID:
30658968
3.

Culprit Drugs Induce Specific IL-36 Overexpression in Acute Generalized Exanthematous Pustulosis.

Meier-Schiesser B, Feldmeyer L, Jankovic D, Mellett M, Satoh TK, Yerly D, Navarini A, Abe R, Yawalkar N, Chung WH, French LE, Contassot E.

J Invest Dermatol. 2019 Apr;139(4):848-858. doi: 10.1016/j.jid.2018.10.023. Epub 2018 Nov 2.

PMID:
30395846
4.

Immuno-monitoring reveals an extended subclinical disease activity in tocilizumab-treated giant cell arteritis.

Gloor AD, Yerly D, Adler S, Reichenbach S, Kuchen S, Seitz M, Villiger PM.

Rheumatology (Oxford). 2018 Oct 1;57(10):1795-1801. doi: 10.1093/rheumatology/key158.

PMID:
29961816
5.

Mechanisms leading to T-cell activation in drug hypersensitivity.

Meng X, Yerly D, Naisbitt DJ.

Curr Opin Allergy Clin Immunol. 2018 Aug;18(4):317-324. doi: 10.1097/ACI.0000000000000458. Review.

6.

Severe Cutaneous Adverse Drug Reactions: Presentation, Risk Factors, and Management.

Mustafa SS, Ostrov D, Yerly D.

Curr Allergy Asthma Rep. 2018 Mar 24;18(4):26. doi: 10.1007/s11882-018-0778-6. Review.

PMID:
29574562
7.

Elevated levels of the antimicrobial peptide LL-37 in hidradenitis suppurativa are associated with a Th1/Th17 immune response.

Thomi R, Schlapbach C, Yawalkar N, Simon D, Yerly D, Hunger RE.

Exp Dermatol. 2018 Feb;27(2):172-177. doi: 10.1111/exd.13482. Epub 2018 Jan 5.

PMID:
29222824
8.

Drug hypersensitivity: We need to do more.

Pichler WJ, Yerly D.

J Allergy Clin Immunol. 2018 Jan;141(1):89-91. doi: 10.1016/j.jaci.2017.11.002. Epub 2017 Nov 16. No abstract available.

PMID:
29155149
9.

A novel recycling mechanism of native IgE-antigen complexes in human B cells facilitates transfer of antigen to dendritic cells for antigen presentation.

Engeroff P, Fellmann M, Yerly D, Bachmann MF, Vogel M.

J Allergy Clin Immunol. 2018 Aug;142(2):557-568.e6. doi: 10.1016/j.jaci.2017.09.024. Epub 2017 Oct 23.

PMID:
29074459
10.

Structural Elements Recognized by Abacavir-Induced T Cells.

Yerly D, Pompeu YA, Schutte RJ, Eriksson KK, Strhyn A, Bracey AW, Buus S, Ostrov DA.

Int J Mol Sci. 2017 Jul 7;18(7). pii: E1464. doi: 10.3390/ijms18071464.

11.

Interleukin-32 is highly expressed in lesions of hidradenitis suppurativa.

Thomi R, Yerly D, Yawalkar N, Simon D, Schlapbach C, Hunger RE.

Br J Dermatol. 2017 Nov;177(5):1358-1366. doi: 10.1111/bjd.15458. Epub 2017 Sep 27.

PMID:
28301691
12.

Reduced pro-inflammatory profile of γδT cells in pregnant patients with rheumatoid arthritis.

Tham M, Schlör GR, Yerly D, Mueller C, Surbek D, Villiger PM, Förger F.

Arthritis Res Ther. 2016 Jan 22;18:26. doi: 10.1186/s13075-016-0925-1.

13.

Drug Hypersensitivity: How Drugs Stimulate T Cells via Pharmacological Interaction with Immune Receptors.

Pichler WJ, Adam J, Watkins S, Wuillemin N, Yun J, Yerly D.

Int Arch Allergy Immunol. 2015;168(1):13-24. doi: 10.1159/000441280. Epub 2015 Nov 3. Review.

14.

Abacavir induced T cell reactivity from drug naïve individuals shares features of allo-immune responses.

Adam J, Wuillemin N, Watkins S, Jamin H, Eriksson KK, Villiger P, Fontana S, Pichler WJ, Yerly D.

PLoS One. 2014 Apr 21;9(4):e95339. doi: 10.1371/journal.pone.0095339. eCollection 2014.

15.

T cells infiltrate the liver and kill hepatocytes in HLA-B(∗)57:01-associated floxacillin-induced liver injury.

Wuillemin N, Terracciano L, Beltraminelli H, Schlapbach C, Fontana S, Krähenbühl S, Pichler WJ, Yerly D.

Am J Pathol. 2014 Jun;184(6):1677-82. doi: 10.1016/j.ajpath.2014.02.018. Epub 2014 Apr 13.

PMID:
24731753
16.

Oxypurinol directly and immediately activates the drug-specific T cells via the preferential use of HLA-B*58:01.

Yun J, Marcaida MJ, Eriksson KK, Jamin H, Fontana S, Pichler WJ, Yerly D.

J Immunol. 2014 Apr 1;192(7):2984-93. doi: 10.4049/jimmunol.1302306. Epub 2014 Mar 3.

17.

Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response.

Yun J, Mattsson J, Schnyder K, Fontana S, Largiadèr CR, Pichler WJ, Yerly D.

Clin Exp Allergy. 2013 Nov;43(11):1246-55. doi: 10.1111/cea.12184.

PMID:
24152157
18.

HLA haplotype determines hapten or p-i T cell reactivity to flucloxacillin.

Wuillemin N, Adam J, Fontana S, Krähenbühl S, Pichler WJ, Yerly D.

J Immunol. 2013 May 15;190(10):4956-64. doi: 10.4049/jimmunol.1202949. Epub 2013 Apr 17.

19.

Human leukocyte antigens (HLA) associated drug hypersensitivity: consequences of drug binding to HLA.

Yun J, Adam J, Yerly D, Pichler WJ.

Allergy. 2012 Nov;67(11):1338-46. doi: 10.1111/all.12008. Epub 2012 Sep 3. Review.

PMID:
22943588
20.

Avidity determines T-cell reactivity in abacavir hypersensitivity.

Adam J, Eriksson KK, Schnyder B, Fontana S, Pichler WJ, Yerly D.

Eur J Immunol. 2012 Jul;42(7):1706-16. doi: 10.1002/eji.201142159. Epub 2012 Jun 14.

21.

NKp46+ cells express granulysin in multiple cutaneous adverse drug reactions.

Schlapbach C, Zawodniak A, Irla N, Adam J, Hunger RE, Yerly D, Pichler WJ, Yawalkar N.

Allergy. 2011 Nov;66(11):1469-76. doi: 10.1111/j.1398-9995.2011.02677.x. Epub 2011 Aug 5.

PMID:
21819408
22.

Delayed drug hypersensitivity: models of T-cell stimulation.

Adam J, Pichler WJ, Yerly D.

Br J Clin Pharmacol. 2011 May;71(5):701-7. doi: 10.1111/j.1365-2125.2010.03764.x. Review.

23.

Telomerase-specific GV1001 peptide vaccination fails to induce objective tumor response in patients with cutaneous T cell lymphoma.

Schlapbach C, Yerly D, Daubner B, Yawalkar N, Hunger RE.

J Dermatol Sci. 2011 May;62(2):75-83. doi: 10.1016/j.jdermsci.2011.02.001. Epub 2011 Feb 15.

PMID:
21377838
24.

Drug hypersensitivity reactions: pathomechanism and clinical symptoms.

Pichler WJ, Adam J, Daubner B, Gentinetta T, Keller M, Yerly D.

Med Clin North Am. 2010 Jul;94(4):645-64, xv. doi: 10.1016/j.mcna.2010.04.003. Review.

PMID:
20609855
25.

In vitro detection of cytotoxic T and NK cells in peripheral blood of patients with various drug-induced skin diseases.

Zawodniak A, Lochmatter P, Yerly D, Kawabata T, Lerch M, Yawalkar N, Pichler WJ.

Allergy. 2010 Mar;65(3):376-84. doi: 10.1111/j.1398-9995.2009.02180.x. Epub 2009 Sep 30.

PMID:
19793058
26.

Design, expression, and processing of epitomized hepatitis C virus-encoded CTL epitopes.

Yerly D, Heckerman D, Allen T, Suscovich TJ, Jojic N, Kadie C, Pichler WJ, Cerny A, Brander C.

J Immunol. 2008 Nov 1;181(9):6361-70.

27.

Increased cytotoxic T-lymphocyte epitope variant cross-recognition and functional avidity are associated with hepatitis C virus clearance.

Yerly D, Heckerman D, Allen TM, Chisholm JV 3rd, Faircloth K, Linde CH, Frahm N, Timm J, Pichler WJ, Cerny A, Brander C.

J Virol. 2008 Mar;82(6):3147-53. doi: 10.1128/JVI.02252-07. Epub 2008 Jan 9.

28.

Targets of emerging therapies for viral hepatitis B and C.

Yerly D, Di Giammarino L, Bihl F, Cerny A.

Expert Opin Ther Targets. 2006 Dec;10(6):833-50. Review.

PMID:
17105371

Supplemental Content

Support Center